Clover Health Investments, Corp. (CLOV)
Clover Health Investments, Corp. (CLOV) Presents at UBS Global Healthcare Conference 2025 Transcript
Clover Health Investments, Corp. ( CLOV ) UBS Global Healthcare Conference 2025 November 11, 2025 11:00 AM EST Company Participants Peter Kuipers - Chief Financial Officer Presentation Unknown Analyst Okay. All right.
Why Fast-paced Mover Clover Health Investments (CLOV) Is a Great Choice for Value Investors
Clover Health Investments (CLOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
CLOV Q3 Earnings Miss, Stock Falls on Raised Insurance BER View
Clover Health's Q3 sales soar 50%, but higher Insurance costs and a raised BER outlook weigh on investor sentiment.
Clover Health Investments, Corp. (CLOV) Q3 2025 Earnings Call Transcript
Clover Health Investments, Corp. ( CLOV ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Ryan Schmidt - Investor Relations Analyst Andrew Toy - Co-Founder, CEO & Director Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong Presentation Operator Hello, and welcome to Clover Health's Third Quarter 2025 Earnings Call. [Operator Instructions] Also, as a reminder, this conference is being recorded today.
Clover Health Investments, Corp. (CLOV) Reports Break-Even Earnings for Q3
Clover Health Investments, Corp. (CLOV) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to a loss of $0.02 per share a year ago.
Clover Health Surges: Profit, Revenue, Membership Up
Clover Health Investments (NASDAQ: CLOV) delivered its second consecutive profitable quarter tonight, beating earnings expectations and extending a streak of operational improvement that has quietly reshaped the Medicare Advantage insurer's narrative.
Clover Health Investments (CLOV) Upgraded to Buy: Here's What You Should Know
Clover Health Investments (CLOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Fast-paced Momentum Stock Clover Health Investments (CLOV) Is Still Trading at a Bargain
Clover Health Investments (CLOV) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Bears are Losing Control Over Clover Health Investments (CLOV), Here's Why It's a 'Buy' Now
Clover Health Investments (CLOV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Clover Health: Short-Term Pain Hides Its Long-Term Profitability Potential
While Clover Health's Q2 earnings showed continued member and revenue growth, it dropped 30% since then due to higher medical costs that impacted all MA plan providers. Clover Health still maintains industry-leading medical cost ratios despite the short-term cost headwinds, a testament to its tech-based business model. The implementation of negotiated drug prices in 2026, combined with the 5.06% MA payout increase by CMS and the 5% quality bonus, could help Clover offset the higher medical costs.
CLOV Q2 Earnings In Line, Stock Falls on Raised Insurance BER View
Clover Health's Q2 revenues rise 34%, but raised Insurance BER guidance and margin pressures cause shares to tumble post-earnings.
Clover Health Investments, Corp. (CLOV) Q2 2025 Earnings Call Transcript
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Andrew Toy - Co-Founder, CEO & Director Peter J. Kuipers - Chief Financial Officer Ryan Schmidt - Corporate Participant Investor Relations Analyst - Corporate Participant Conference Call Participants John Granville Pinney - Canaccord Genuity Corp., Research Division Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Operator Ladies and gentlemen, good afternoon, and welcome to the Clover Health Second Quarter 2025 Earnings Conference Call.
